Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples